Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 9/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133266 | 0.78 | GRIN2B (0.56) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL4462505 | 0.74 | GRIN2B (0.66) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL27059331 | 0.73 | SMN1; SMN2 (0.59) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL28978073 | 0.72 | SMN1; SMN2 (0.53) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL2896415 | 0.72 | SMN1; SMN2 (0.76) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL19732305 | 0.72 | SMN1; SMN2 (0.57) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL15018080 | 0.71 | SMN1; SMN2 (0.60) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL5633495 | 0.71 | SMN1; SMN2 (0.56) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL1851354 | 0.71 | SMN1; SMN2 (0.74) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL25172797 | 0.71 | SMN1; SMN2 (0.50) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | LAIRD ELLEN | 2009-07-09 | — | — | US | disclosed |
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1846391-A2 | RAF INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20060189627-A1 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2006084015-A2 | RAF INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189627-A1 | RAF inhibitor compounds and methods | BRAF, RAF1, ARAF | GRIN2B 4343/4885CYP2D6 3993/4885CYP2C9 4377/4885 |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | BRAF, RAF1, ARAF | GRIN2B 4343/4885CYP2D6 3993/4885CYP2C9 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.